Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Inhibition of SREBP With Fatostatin Does Not Attenuate Early Diabetic Nephropathy in Male Mice.

Endocrinology | 2018

Sterol regulatory element binding protein (SREBP) is an important potential mediator of kidney fibrosis and is known to be upregulated in diabetic nephropathy. We evaluated the effectiveness of SREBP inhibition as treatment of diabetic nephropathy. Type 1 diabetes was induced in uninephrectomized male CD1 mice with streptozotocin. The mice were treated with the SREBP inhibitor fatostatin for 12 weeks. At the endpoint, kidney function and pathologic findings were assessed. Fatostatin inhibited the increase of both isoforms of SREBP (types 1 and 2) in diabetic kidneys. Treatment attenuated basement membrane thickening but did not improve hyperfiltration, albuminuria, or kidney fibrosis in diabetic mice. The treatment of nondiabetic mice with fatostatin led to hyperfiltration and increased the glomerular volume to levels seen in diabetic mice. This was associated with increased renal inflammation and a trend toward increased renal fibrosis. Both in vivo and in cultured renal proximal tubular epithelial cells, fatostatin increased the expression of the proinflammatory cytokine monocyte chemoattractant protein-1. Thus, SREBP inhibition with fatostatin not only is ineffective in preventing diabetic nephropathy but also leads to kidney injury in nondiabetic mice. Further research on the efficacy of other SREBP inhibitors and the specific roles of SREBP-1 and SREBP-2 in the treatment and pathogenesis of diabetic nephropathy is needed.

Pubmed ID: 29420703 RIS Download

Mesh terms: Animals | Diabetes Mellitus, Type 1 | Diabetic Nephropathies | Humans | Kidney | Male | Mice | Pyridines | Receptors, CCR2 | Signal Transduction | Sterol Regulatory Element Binding Protein 1 | Sterol Regulatory Element Binding Protein 2 | Thiazoles

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


TGFbeta RI (V-22) antibody (antibody)

RRID:AB_632493

This monoclonal antibody targets TGFbeta RI (V-22)

View all literature mentions

Smad3 Antibody (antibody)

RRID:AB_11031542

This unknown targets Smad3

View all literature mentions

Caspase-3 (8G10) Rabbit mAb antibody (antibody)

RRID:AB_2069872

This monoclonal antibody targets Caspase-3 (8G10) Rabbit mAb

View all literature mentions

SREBP1 antibody (antibody)

RRID:AB_778069

This polyclonal antibody targets SREBP1

View all literature mentions

Smooth Muscle Actin Monoclonal Antibody (1A4) (antibody)

RRID:AB_557419

This monoclonal antibody targets Smooth Muscle Actin

View all literature mentions

SREBP-2 (N-19) antibody (antibody)

RRID:AB_2194252

This polyclonal antibody targets SREBP-2 (N-19)

View all literature mentions

CD 3 (Pan-T) antibody (antibody)

RRID:AB_2335677

This polyclonal antibody targets Synthetic peptide comprising amino acids 156-168 from the cytoplasmic part of the human CD3__chain coupled to thyroglobulin

View all literature mentions

Monoclonal Anti-alpha-Tubulin antibody produced in mouse (antibody)

RRID:AB_477582

This monoclonal antibody targets alpha-Tubulin antibody produced in mouse

View all literature mentions